Biohaven Pharmaceutical Holding Return on Investment 2016-2022 | BHVN

Current and historical return on investment (ROI) values for Biohaven Pharmaceutical Holding (BHVN) over the last 10 years.
Biohaven Pharmaceutical Holding ROI - Return on Investment Historical Data
Date TTM Net Income LT Investments & Debt Return on Investment
2022-03-31 $-0.52B $0.17B 2050.98%
2021-12-31 $-0.71B $-0.12B 1018.05%
2021-09-30 $-0.72B $0.03B 1005.59%
2021-06-30 $-0.74B $-0.18B 1124.24%
2021-03-31 $-0.73B $-0.01B 3565.85%
2020-12-31 $-0.65B $-0.13B 3445.33%
2020-09-30 $-0.61B $0.05B -4880.00%
2020-06-30 $-0.54B inf%
2020-03-31 $-0.58B inf%
2019-12-31 $-0.48B inf%
2019-09-30 $-0.39B inf%
2019-06-30 $-0.36B inf%
2019-03-31 $-0.20B inf%
2018-12-31 $-0.22B inf%
2018-09-30 $-0.20B inf%
2018-06-30 $-0.19B inf%
2018-03-31 $-0.18B inf%
2017-12-31 $-0.11B -2038.10%
2017-09-30 $-0.10B -2040.00%
2017-06-30 $-0.09B -1800.00%
2017-03-31 $-0.07B $0.02B -1440.00%
2016-12-31 $-0.06B $-0.00B 24400.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $10.248B $0.463B
Biohaven Pharmaceutical is a commercial-stage biotechnology company focused on developing, and commercializing products, primarily in the fields of central nervous system diseases, including neurological and rare disorders.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00